Animation - Understanding NSCLC Treatment for Less Common Mutations: ALK, BRAF, ROS1, HER2, MET

Slide Show - Understanding NSCLC Treatment for Less Common Mutations: ALK, BRAF, ROS1, HER2, MET

Expert Videos

1. What is a gene mutation and how does it relate to lung cancer?

2. How do doctors test for genetic mutations in lung cancer and why is it important?

3. What is comprehensive biomarker testing for lung cancer? What do I need to know?

4. What is an ALK rearrangement in lung cancer?

5. How do doctors treat ALK-rearranged lung cancer?

6. What is a BRAF mutation in lung cancer?

7. How do doctors treat lung cancer with BRAF mutations?

8. What is a ROS1 mutation in lung cancer?

9. How do doctors treat lung cancer with ROS1 mutations?

10. What is a HER2 mutation in lung cancer?

11. How do doctors treat lung cancer with HER2 mutations?

12. What is a MET mutation in non-small cell lung cancer (NSCLC)?

13. How do doctors treat lung cancer with MET mutations?

Expert Video - How do doctors treat lung cancer with HER2 mutations?

Medical oncologist Dr. Naomi Fujioka of the University of Minnesota provides an overview of how doctors treat HER2-mutated lung cancer. She discusses trastuzumab deruxtecan, which is an antibody-drug conjugate, and discusses some of the side effects of treatment. She also talks about clinical trials to develop new treatments for HER2-mutated lung cancer.

Click here to take our SURVEY
Your feedback is important to us! We will use your feedback to develop future areas of content about lung cancer which will help other patients, caregivers and families.

NSCLC Treatment When You Have an EGFR Mutation

NSCLC Treatment Options When You Have an EGFR Mutation

NSCLC Treatment When You Have a KRAS Mutation

NSCLC Treatment Options When You Have a KRAS Mutation

Immunotherapy for NSCLC with PD-1 and PD-L1 Biomarkers

Understanding Non-Small Cell Lung Cancer (NSCLC)

Understanding Small Cell Lung Cancer (SCLC)

Screening for Lung Cancer

Lung Cancer Screening for Black Americans

Lung Cancer Screening for Native Americans

Diagnosis and Screening of Lung Cancer

Staging of Lung Cancer

Understanding Biomarker Testing in Non-Small Cell Lung Cancer

Treatment and Management of Lung Cancer

Immunotherapy for Lung Cancer

Targeted Therapy in Non-Small Cell Lung Cancer

Understanding Clinical Trials in Lung Cancer

Lung Cancer Clinical Trials and the US Black Community

Lung Cancer Clinical Trials and Native Americans

Understanding Prehabilitation for Lung Cancer Surgery

Your Prehabilitation Plan for Lung Cancer Surgery

Section: NSCLC Treatment for Less Common Mutations: ALK, BRAF, ROS1, HER2, MET

Animation - Understanding NSCLC Treatment for Less Common Mutations: ALK, BRAF, ROS1, HER2, MET

Slide Show - Understanding NSCLC Treatment for Less Common Mutations: ALK, BRAF, ROS1, HER2, MET

Expert Videos

1. What is a gene mutation and how does it relate to lung cancer?

2. How do doctors test for genetic mutations in lung cancer and why is it important?

3. What is comprehensive biomarker testing for lung cancer? What do I need to know?

4. What is an ALK rearrangement in lung cancer?

5. How do doctors treat ALK-rearranged lung cancer?

6. What is a BRAF mutation in lung cancer?

7. How do doctors treat lung cancer with BRAF mutations?

8. What is a ROS1 mutation in lung cancer?

9. How do doctors treat lung cancer with ROS1 mutations?

10. What is a HER2 mutation in lung cancer?

11. How do doctors treat lung cancer with HER2 mutations?

12. What is a MET mutation in non-small cell lung cancer (NSCLC)?

13. How do doctors treat lung cancer with MET mutations?

Patient Stories:

Mr. Satterfield's Story

Sharon’s Story

Terri's Story

Tricia's Story

This educational activity has been developed by A Breath of Hope Lung Foundation and Mechanisms in Medicine Inc.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Bristol-Myers Squibb Foundation Inc., Bristol-Myers Squibb Grants and Giving, Foundation Medicine, Genentech, Jazz Pharmaceuticals, Merck Sharp & Dohme LLC, Neogenomics, Novartis, Pfizer, and Takeda Oncology.

This website is part of the Animated Patient^® series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed shared decisions, and partner with their healthcare professionals for optimal outcomes.